Vasospastic Syndrome: definition, prevalence, detection {#Sec1}
=======================================================

Vasospastic Syndrome or vascular deregulation (VD) is defined as an inappropriate constriction or insufficient dilatation in the microcirculation (see Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Alterations in conjunctival vessels in patients with vasospasm \[[@CR1]\]

Generally, vasospasm is considered as primary and secondary one. Secondary VD is due to other diseases such as autoimmune one. Primary VD is prevalent in younger subpopulation, can potentially predispose to several disorders being, therefore, particularly attractive for predictive diagnostics and individualised treatment. Primary VD demonstrates following particularities: it occurs more frequent in females manifested in puberty and moderating with agethis phenomenon is even more frequent in Japanese population compared to Caucasian \[[@CR2]\]usually academics are more affected by VD \[[@CR3]\]to clinical signs belong an inborn increased sensitivity to any kind of stress provocation (mechanical, cold, emotion, etc.), altered drug sensitivity, frequently cold extremities, altered sleep behaviour, reduced feeling of thirst, low blood-pressure, reduced body-mass-index, more frequent migraine compared to general population \[[@CR1], [@CR4], [@CR5]\]Compared to general population, vasospastic individuals tend to a meticulous personality and successful professional career \[[@CR6]\].

A valuable diagnostic tool for the ascertainment of vasospastic diathesis is the nailfold capillary microscopy (see Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Nailfold capillary microscopy (right) enables the monitoring of microcirculation and cold provocation of vasospasm in fingers (left) \[[@CR1]\]

The best known blood-related risk factor is an increased plasma level of endothelin-1 \[[@CR1]\]. Since Vasospastic Syndrome is a frequent phenomenon in young subpopulations, this makes the task of prediction and targeted prevention of "down-stream" related pathologies particularly attractive from several points of view including economical aspects.

What is the impact of vascular deregulation in glaucoma pathology? {#Sec2}
==================================================================

A wealth of literature points to the importance of haemodynamics in glaucoma pathology. Vasospasm is frequently observed in glaucoma patients \[[@CR1], [@CR7]\]. Ocular ischemia resulting from blood-flow deficits may play a major role in the initiation of glaucoma: hypoxia, followed by high secretion of excitatory amino acids and elevated levels of intracellular calcium results in the process of retinal ganglion cell death \[[@CR8]--[@CR10]\]. In our previous studies, we have demonstrated stable alterations in gene expression of circulating leucocytes isolated from glaucoma patients compared to healthy controls \[[@CR11]--[@CR14]\]. Further, significant similarities in expression profiles of circulating leucocytes between vasospastic individuals and glaucoma patients have been recently published \[[@CR15]\]. However, the same publication reports also significant dissimilarities of molecular patterns as compared to both glaucoma patients and healthy controls; consequently, a development of both degenerative and non-degenerative pathologies different from glaucomatous optic nerve degeneration but related to primary vasospasm cannot be excluded in vasospastic individuals.

What is the potential impact of prediction and prevention of glaucoma in healthy vasospastic individuals? {#Sec3}
=========================================================================================================

Worldwide, 67 million patients are affected by the neurodegenerative eye disease glaucoma. Glaucomatous optic neuropathy (GON) is the second leading cause of permanent vision loss. GON is a chronic degenerative process, the onset of which is not possible to monitor by currently existing diagnostic tools. Early treatment has been reported to be highly beneficial for well-timed treatment measures to slow-down the disease progression \[[@CR16]\]. As review in this journal-issue \[[@CR17]\], molecular pathomechanisms of glaucoma demonstrate both a considerable overlap and remarkable particularities to some other neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. Thus *versus* controls, the neuronal thread protein (NTP) demonstrates enhanced expression levels in glaucoma, patients with Down Syndrome, Alzheimer's and some other neurodegenerative diseases indicating the axonal lesions. However, whereas the accumulation of *TAU*-protein is characteristic for Alzheimer's disease and other tauopathies, glaucoma patients do not demonstrate an increase in the target protein *versus* controls \[[@CR16], [@CR18]\]. Therefore, a potential predisposition of vasospastic individuals to related pathologies should be thoroughly examined. In this context, molecular pathways involved in vasospastic deregulation should be investigated from viewpoint of identification of possible similarities as well as dissimilarities in molecular pathways between healthy vasospastic individuals and potential related pathologies developed later in lifespecificity for predictive diagnostics of glaucoma pathology in predisposed vasospastic individuals should be strictly validated against several control groups including other neuro/degenerative diseasesselection of molecular targets should be performed for vasospastic individuals in favour of non-invasive (blood test) diagnostic approaches followed by personalised treatment towards individual predisposition to single pathologies.

A monitoring of the pathology-specific molecular patterns is particularly valuable to develop reliable diagnostic approaches before the manifest pathology. Predictive tests can specify individual predisposition for well-timed preventive measures.

Similarities in subcellular images of DNA-damage and -repair capacity in vasospasm and glaucoma {#Sec4}
===============================================================================================

Research work focused on the *ex vivo* comparative investigations of DNA damage in circulated leucocytes (CL) isolated from patients with glaucoma demonstrated significantly enhanced DNA damage compared to both healthy vasospastic and non-vasospastic individuals \[[@CR19]\]. Comparative "Comet Assay" analysis revealed patterns of comets typical for glaucoma patients as shown in Fig. [3](#Fig3){ref-type="fig"}. Fig. 3*Ex vivo* "Comet Assay"-analysis of DNA damage in circulating leucocytes of glaucoma patients and non-glaucomatous vasospastic individuals *versus* healthy controls \[[@CR19]\]. Figures A--D give examples of images typical for **a**. control group, **b**. group of vasospastic individuals, **c**. group of normal-tension glaucoma patients, and **d**. group of high-tension glaucoma patients. Comet-patterns typical for healthy controls (A) show that chromosomal DNA is localised mainly to heads of comets (intact DNA). In contrast, images B, C, and D demonstrate clearly damaged DNA (visible comet-tails and diffuse comet-heads). Evaluation of the shape of a comet allows for assessment of DNA damage. Individual migration patterns are demonstrated in groups corresponding to the images A--D by the evaluation of comet-classes (class number progression corresponds to increasing damage degree) as described earlier \[[@CR20]\]. Figure E shows mean values calculated for relative DNA damage in following groups as compared to the control group (100%): VI---vasospastic individuals (102 ± 7%), *NTG* normal-tension glaucoma (160 ± 13%), and *HTG* high-tension glaucoma (128 ± 10%) \[[@CR18]\]

Although DNA damage in the vasospastic non-glaucomatous group is not found to be significantly increased *versus* healthy controls, DNA from vasospastic individuals showed highly group-specific comet-patterns with the degree of damage intermediate between healthy controls and glaucoma patients. These findings indicate "comet assay" profiling of DNA-damage in CL as a potentially powerful tool for the non-invasive early/predictive molecular diagnostics of glaucoma disease in vasospastic individuals \[[@CR18]\]. Furthermore, unrepaired DNA-damage in vasospastic individuals can lead to several pathologies different from glaucomatous optic nerve degeneration. This predisposition should be thoroughly investigated and the specificity of "Comet Assay"-patterns of vasospastic individuals should be validated comparing with patterns of other degenerative and non-degenerative pathologies. Thus, "Comet Assay"-analysis as a suitable tool for biomarkers has also been suggested for another neurodegenerative disorder---Alzheimer's disease \[[@CR21]\]. "Comet Assay"-analysis reveals enhanced DNA damage in both high- and normal-tension glaucoma \[[@CR19]\]. Whether the level of DNA-damage correlates with disease severity, or not remains currently unclear. Further studies should also evaluate, whether a significant increase in DNA damage of leucocytes of glaucoma patients is caused by either disease specific stress factors, such as local ischemic/reperfusion events, and/or decreased capacity of DNA-repair machinery. There is some evidence for both eventualities: simultaneous up-regulation of *p53* (stress regulated gene) and down-regulation of *XPGC* (essential member of DNA-repair machinery) have been *ex vivo* demonstrated in CL of glaucoma patients \[[@CR22]\] and represent potential molecular blood markers for the disease.

Similarities in expression patterns detected in circulating leucocytes of vasospastic individuals and glaucoma patients {#Sec5}
=======================================================================================================================

2D-PAGE {#Sec6}
-------

Protein-patterns in circulating leucocytes demonstrate clear similarities between vasospasm and normal-tension glaucoma *versus* controls. Moreover, protein-clusters can be considered for predictive imaging of healthy vasospastic individuals to glaucoma as shown in Fig. [4](#Fig4){ref-type="fig"}. Fig. 4Proteomics-imaging of blood-biomarkers (*ex vivo* identification in circulating leucocytes) specific for normal-tension glaucoma (NTG). **A**. Top: The pathology-specific protein-cluster is completely suppressed in both NTG and vasospasm in contrast to controls. **B**. Bottom: The marked protein SSP2602 is highly up-regulated in both NTG and vasospasm; this protein normally is not expressed by circulating leucocytes of controls---healthy individuals without vasospasm \[[@CR22]\]

Expression array {#Sec7}
----------------

The image of hybridised "AtlasTM Human Cardiovascular Array" revealed similarities as well as alterations in expression-patterns among normal-tension glaucoma (NTG), high-tension glaucoma (HTG), and VD groups *versus* controls are summarised in Table [1](#Tab1){ref-type="table"}. Table 1Numbers of genes an expression of which is either differential or equal among the groups tested as shown by "[Expression array](#Sec7){ref-type="sec"}". Thereby, 108 genes were found to be differentially expressed between NTG and HTG groups. 34 genes demonstrated similar alteration for vasospastic individuals (VD) and both glaucoma-patient groups when compared to the healthy controls (see these genes listed in Table [2](#Tab2){ref-type="table"})Differential to controlVD equal toVD Differential toNTG → 146Control → 528NTG → 109HTG → 68NTG → 48K → 60VD → 60HTG → 43HTG → 43NTG = HTG → 53![](13167_2010_32_Figa_HTML.gif){#d29e548}NTG = HTG → 21

Compared to the control group the expression of 146, 68, and 60 genes were found to be altered in NTG, HTG, and VD groups respectively; the same 53 genes were differentially expressed in both NTG and HTG groups *versus* controls. Among 146 genes differentially expressed specifically in NTG group we monitored 48 and 53 genes which were similarly expressed either in VD or in HTG groups respectively. Among 68 genes differentially expressed specifically in HTG group we found 43 genes to be similarly expressed in VD group only. The highest difference---146 genes---was found to be between NTG and control groups. In contrast, the lowest difference---21 genes---was demonstrated to be between VD and the overlap of NTG/HTG.

34 genes demonstrated similar expressional alterations in NTG, HTG, and VD groups *versus* controls as given in Table [2](#Tab2){ref-type="table"}. As the differentially expressed overlap VD/NTG/HTG was compared with the control group, following most significant difference was monitored: Table 2Differentially expressed genes (altogether 34 ones as also summarised in Table [1](#Tab1){ref-type="table"}) *versus* controls, the transcriptional levels of which were similar for VD, NTG and HTG groups \[[@CR18]\]Double-spot position in "EA"-image exp. difference vs. controlName of gene as given in "Atlas^TM^ Human Cardiovascular Array"GenBank AccessionSwissProt AccessionGene/Protein Classification A7dP2Y purinoceptor 7 (P2Y7); leukotriene B4 receptor; Chemoattractant receptor-like1 (CMKRL1)U41070Q15722Other receptors (by Ligands) increasedQ13305G Protein-Coupled ReceptorsQ92641 A7eRetinoic acid (Vitamin-A1-Säure) receptor gamma 1 (RAR-gamma 1; RARG)M24857P13631Transcription Activator & Repressors increasedM38258Hormone ReceptorsM57707Nuclear ReceptorsM32074 B1nAndrogen receptor coactivator 70-kDa subunit (ARA70)L49399Q13772Transcription Activator & Repressors increased B4cG protein-activated inward potassium channel 4 (GIRK4); heart K+/ATP channel (KATP1); cardiac inward rectifyer (CIR); KIR3.4U39195P48544Voltage-gated Ion Channels increasedQ92807 B4dSodium/calcium exchanger 1 precursor; Na+/Ca2+-exchange protein 1M91368P32418Symporters & Antiporters increased B4eMultidrug resistance protein 3 (MDR3); P-Glycoprotein 3 (PGY3)M23234P21439Drug-Resistance proteins increasedXenobic TransportersABC transporters B5fEndothelial nitric oxide synthase (EC-NOS)M93718P29474Other Metabolism Enzymes increasedOther Intracellular Transducers, Effectors & Modulators B6dIntercellular adhesion molecule 1 precursor (ICAM1); major group rhinovirus receptor; CD54 antigenJ03132P05362Matrix Adhesion Receptors increased B7gCalcium & integrin-binding protein (CIB)U85611Q99828Calcium-Binding proteins increased C1gCadherin 7 (CDH7)AF047826O60574Cell Surface Antigens increasedCell-Cell Adhesion Receptors C1hIntestinal peptide-associated transporter 1 (HPT1)U07969Q12864Other Cell Adhesion proteins increasedOther Cell Adhesion ProteinsOther Facilitated Diffusion proteins C2iGAP junction alpha-5 proteinL34954P36382Cell-Cell Adhesion Receptors increasedOther Membrane Channels & Transporters C3 mIntegrin beta 2 (ITGB2); cell surface adhesion glycoprotiens LFA-1/CR3/p150, 95 beta subunit precursor; CD18 antigen;M15395P05107Cell-Cell Adhesion Receptors increasedComplement receptor C3 beta subunitQ16418 D1 mCardiac LIM domain protein; muscle LIM protein; cystein-rich protein 3 (CRP3); LIM-only protein 4U49837P50461Basic Transcription Factors increasedOther Transcription ProteinsDNA Synthesis, Recombination & Repair Proteins D1nCardiotrophin-1 (CT1)U43030Q16619Growth Factors, cytokines & Chemokines increased D2nMatrix metalloproteinase 16 (MMP-16)D83646P51512Chromatin Proteins increasedMetalloproteinases D4aTIMP-3U14394P35625Extracellular Matrix Proteins increasedProteinase Inhibitor D4bTIMP-4U76456Q99727Extracellular Matrix Proteins increasedProteinase Inhibitor D4dSterol regulatory element-binding transcription factor 1U00968P36956Basic trnascription Factors increasedOther Apoptosis-Associated Proteins D4eSterol regulatory element-binding transcription factor 2U02031Q12772Basic trnascription Factors increasedOther Apoptosis-Associated Proteins D5 hRab geranylgeranyl transferase bety subunitY08201P53611Trafficking & Targeting Proteins increasedQ92697Protein Modification EnzymesGTP/GDP Exchangers & GTPase Activity Modulators D6 mMuscle-specific DNase I-like precursor (DNase 1 L1; DNL 1 L); Dnase XX90392P49184DNA Synthesis, Recombination & Repair Proteins decreasedL40817Apoptosis-Associated ProteinsU06846 E1bLanosterol synthase (LSS); oxidosqualene lanosterol cyclase (OSC)D63807P48449Complex Lipid Metabolism increased E3nNADPH-cytochrome p450 reductaseS90469Q16455Xenobic Metabolism increasedP16435 E4 gSteroid 5 alpha reductase 1 (SRD5A1); 3-oxo-5-alpha steroid 4 dehydrogenase 1M32313P18405Complex Lipid Metabolism increasedM68886 E4 hSteroid 5-alpha reductase 2 (SRD5A2); 3-oxo-5-alpha steroid 4 dehydrogenase 2M74047P31213Complex Lipid Metabolism increased F2dPregnane X receptor (PXR)AF061056O75469Hormone receptors increasedNuclear Receptors F2eEstrogen-related receptor gammaAF058291O75454Hormone Receptors increasedNuclear Receptors F2fNuclear receptor subfamily 4 group A member 2 (NR4A2); nuclear receptor-related protein 1 (NURR1); transcriptionally inducuble nuclear receptor (TINUR); NOTX75918P43354Hormone Receptors increasedNuclear ReceptorsTranscription Activators & Repressors F2iOrphan nuclear receptor TR4; nuclear receptor subfamily 2 group c member 2 (NR2C2); TAK1U10990P55092Orphan Receptors increasedP49116Nuclear ReceptorsTranscription Activators & Repressors F3aRAR-related orphan receptor CU16997P51449Orphan Receptors increasedNuclear ReceptorsTranscription Activators & Repressors F3eLX receptor alpha (LXR alpha)U22662Q13133Orphan Receptors increased F3iPlatelet-activating factor acetylhydrolase IB alpha subunitL13387P43034Other Metabolism Enzymes increased F7cMyocyte-specific enhancer factor 2A (MEF2A); serum response factor-like protein 1X68505Q02078Basic Transcription FactorsincreasedQ14223Q14224P2Y purinoreceptor 7Na^+^/Ca^2+^ exchange protein 1 (Na^+^/Ca^2+^ EP1)Intercellular adhesion molecule 1 (ICAM1)The cluster of the tissue remodelling metalloproteinases.

This group of gene-transcripts is proposed to be the reliable target to design advanced diagnostic tools for predictive glaucoma diagnosis in healthy vasospastic individuals \[[@CR15]\].

### P2Y purinoreceptor is upregulated in vasospastic individuals and glaucoma patients {#d29e1485}

The movement of leucocytes from blood into tissue is regulated by local production of chemo-attractants---diverse molecules, the chemotactic signal of which is transmitted by G-protein-coupled purinoceptor family P2Y. These receptors respond to chemotactic signals of traumatic, infectious, post-ischemic, autoimmune, and various toxic injuries. Extracellular nucleotides released from the activated platelets and other damaged cell types exacerbate the inflammatory response by cell specific leukotrene generation \[[@CR23]\]. Thus, neutrophils generate leukotrienes B4 (LTB4) which are involved in the genesis of inflammation and oedema because of their effect on vascular permeability, plasma extravasation, diapedesis of white blood cells, and their important role in adaptive immune responses as reviewed by Di Gennaro et al. \[[@CR24]\]. Specifically, a highly enhanced concentration of leukotrienes B4 and C4 has been observed in CSF of patients with multiple sclerosis \[[@CR25]\]. The member of leukotrienes receptors family---LTB4 receptor or P2Y purinoceptor 7---for the first time has been isolated from human erythroleukaemia cell cDNA library \[[@CR26]\]. The stimulation of monocytes, neutrophils, and endothelial cells was suggested to be a physiological role for the LTB4 receptor \[[@CR27]\]. There is a growing body of evidence indicating an important role of LTB4 receptors in regulation of pathologic inflammation. Particularly using animal inflammatory models a reduced disease severity has been shown as LTB4 receptor antagonists have been applied; the same effect has been observed in mice with target deletion of BLT1---a high-affinity LTB4 receptor primarily expressed in leucocytes \[[@CR28]\]. Furthermore, some studies support a potential role of P2Y receptors in controlling intraocular pressure, although additional investigations of the issue are necessary \[[@CR29]\].

### ICAM-1 is upregulated in vasospastic individuals and glaucoma patients {#d29e1512}

Neutrophil-endothelium interactions are implicated in pathological alterations of blood vessel function, potentially leading to circulatory disturbances \[[@CR30]\]. Interactions between blood cells and the vessel wall result in endothelial dysfunction and injury leading to increased blood-brain barrier permeability and even oedema formation \[[@CR31]\]. Penetration of leucocyte into inflamed areas involves complex interaction of leucocytes with endothelium through regulated expression of surface adhesion molecules. Found in this work to be highly expressed in VD, NTG and HTG groups ICAM-1 is believed to be largely responsible for the adhesion and trans-endothelial migration of leucocytes \[[@CR32]\]. This is well in agreement with earlier developed strategies aimed at inhibition of endothelial interactions with leucocytes via use of adhesion molecule monoclonal antibodies, which successfully reduce cerebral ischemia/reperfusion injury, infarct size, and demonstrate a neuroprotective effect generally \[[@CR33]--[@CR35]\]. In our study, highly expressed ICAM-1 was found in leucocytes of glaucoma patients; in contrast, if any only traces of the target expression was detected in the leucocytes of healthy controls.

### Sodium calcium exchanger (NCE) {#d29e1532}

Many studies examined the levels of cytosolic Ca^2+^ (\[Ca^2+^\]~c~) and Na^+^ (\[Na^+^\]~c~) in human blood cells, whereby leucocytes have been the main target of studying the relationship between blood pressure and intracellular content of both ions as reviewed by Horiguchi et al. \[[@CR36]\]. As it has been shown by Horiguchi et al., the resting \[Ca^2+^\]~c~ correlates well with NCE expression indicating NCE expression regulation to be an adaptive mechanism for Ca^2+^ extrusion mediation. The same study observed also a gender effect on \[Ca^2+^\]~c~ / \[Na^+^\]~c~ regulation in circulating leucocytes being in relationship with blood pressure. Further, the role of endothelial intracellular Ca^2+^ concentration in molecular mechanisms of vasoconstriction/vasodilatation has been intensively studied, and the functional association between P2Y purinoceptors, endothelial NO synthesis and calcium transport in terms of vascular regulation is well documented in the literature \[[@CR37], [@CR38]\]. Our findings here clearly demonstrate the up-regulation of both P2Y purinoceptor and Na^+^/Ca^2+^ exchanger in circulating leucocytes of glaucoma patients as well as vasospastic individuals *versus* healthy controls.

### Tissue remodelling metalloproteinases {#d29e1600}

Significantly increased protein expression rates of both latent and active forms of metalloproteinases *MMP-9* and *MT1-MMP* in circulating leucocytes correlate well with the enhanced levels of transcription and with glaucoma diagnosis \[[@CR12]\]. Once activated, both hydrolases necessarily contribute to remodelling or even degeneration of the tissue whereto they are secreted by circulating leucocytes. This up-regulation might be a consequence of repeated mild ischemia/reperfusion postulated for both vasospastic individuals and glaucoma patients \[[@CR18]\]. However, the question as to whether or not there is a correlation between an increased *MMPs* activity and glaucoma severity should be further clarified.

Furthermore, the increased synthesis of tissue-remodelling hydrolases detected in blood of healthy vasospastic individuals can potentially lead to development of some other pathologies which have not been considered as related to vasospasm till now. To the potential list of them belong altered wound-healing, some types of organ-degeneration, increased metastases activity. Large-scale studies are essential to be preformed, in order to prove a potential impact of vasospasm for the above listed pathophysiologic processes / manifested pathologies. This allows a targeted prevention at the stage of pre-lesions, "upstream" disease manifestation.

Concluding remarks {#Sec8}
==================

Expression similarities between glaucoma and VD *versus* controls indicate, on one side, a predisposition of VD individuals to glaucomatous damage, and, on the other side, an important role of vascular component in glaucoma pathology.Expression dissimilarities between VD and glaucoma patients might indicate some glaucoma-specific pathomechanisms which are not involved in the stage of predisposition by VD.Both expression similarities and dissimilarities could be useful to ascertain predictive diagnosis of glaucoma.Molecular rearrangement in leucocytes of both VD and glaucoma patients has been shown to be typical for circulating leucocytes during vascular injury as reviewed by Kunapoli and Daniel \[[@CR39]\] and includes ➢ an up-regulated adhesive protein expression via ICAM1➢ an induced chemo-taxis via P2Y purinoceptors➢ a mobilisation of intracellular Ca^2+^ response via Na^+^/Ca^2+^ exchanger, and➢ the core of tissue remodelling metalloproteinases.Pathology-specific molecular and subcellular patterns may create the basis for the development of more specific and non-invasive molecular imaging technologies in early/predictive glaucoma diagnostics.Development of some other "down-stream" pathologies different from glaucoma but related to primary vasospastic syndrome cannot be excluded.Predictive molecular-profiling in blood can specify individual predisposition for effective prevention to lower costs compared to those for treatment of manifest pathologies.
